Single User License
INR 133820
Site License
INR 267640
Corporate User License
INR 401460

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Anthrax-Pipeline Review, H1 2015

Anthrax-Pipeline Review, H1 2015

  Request for Sample Report

Executive Summary

Anthrax-Pipeline Review, H1 2015


Global Markets Direct's, 'Anthrax-Pipeline Review, H1 2015', provides an overview of the Anthrax's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Anthrax

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Anthrax

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Anthrax Overview 9

Therapeutics Development 10

Pipeline Products for Anthrax-Overview 10

Pipeline Products for Anthrax-Comparative Analysis 11

Anthrax-Therapeutics under Development by Companies 12

Anthrax-Therapeutics under Investigation by Universities/Institutes 16

Anthrax-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Anthrax-Products under Development by Companies 20

Anthrax-Products under Investigation by Universities/Institutes 23

Anthrax-Companies Involved in Therapeutics Development 24

Aduro BioTech, Inc. 24

Aradigm Corporation 25

Bavarian Nordic A/S 26

Bristol-Myers Squibb Company 27

ContraFect Corporation 28

Dynavax Technologies Corporation 29

Elusys Therapeutics, Inc. 30

Emergent BioSolutions Inc. 31

Evolva SA 32

Green Cross Corporation 33

Grifols, S.A. 34

Hawaii Biotech, Inc. 35

iBio, Inc. 36

Immunovaccine, Inc. 37

Innovative Biologics, Inc. 38

Microbiotix, Inc. 39

NanoBio Corporation 40

Navigen Pharmaceuticals, Inc. 41

Oragenics, Inc. 42

PaxVax 43

Pfenex Inc. 44

Planet Biotechnology Inc. 45

Protein Potential, LLC 46

ProThera Biologics, LLC. 47

PsiOxus Therapeutics, Ltd. 48

Revivicor, Inc. 49

SelectX Pharmaceuticals, Inc. 50

Soligenix, Inc. 51

Summit Corporation plc 52

Syntiron LLC 53

Tetraphase Pharmaceuticals Inc. 54

The Medicines Company 55

Vaxin, Inc. 56

Anthrax-Therapeutics Assessment 57

Assessment by Monotherapy Products 57

Assessment by Combination Products 58

Assessment by Target 59

Assessment by Mechanism of Action 61

Assessment by Route of Administration 63

Assessment by Molecule Type 65

Drug Profiles 67

anthrax + plague vaccine-Drug Profile 67

anthrax vaccine-Drug Profile 68

anthrax vaccine-Drug Profile 70

anthrax vaccine-Drug Profile 71

anthrax vaccine-Drug Profile 72

anthrax vaccine-Drug Profile 73

anthrax vaccine-Drug Profile 74

anthrax vaccine-Drug Profile 75

anthrax vaccine-Drug Profile 76

anthrax vaccine-Drug Profile 78

anthrax vaccine-Drug Profile 80

anthrax vaccine next generation-Drug Profile 81

ARD-3100-Drug Profile 82

AV-7909-Drug Profile 84

CF-307-Drug Profile 85

CF-308-Drug Profile 86

ciprofloxacin hydrochloride-Drug Profile 87

DPX-Anthrax-Drug Profile 88

DV-230-Drug Profile 89

EV-021-Drug Profile 90

GC-1109-Drug Profile 91

GREANX-Drug Profile 92

Human Antibody Based Vaccines-Drug Profile 93

KKL-35-Drug Profile 95

MDX-1303-Drug Profile 96

Monoclonal Antibody for Respiratory Anthrax-Drug Profile 98

Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax-Drug Profile 99

MU-1140-Drug Profile 100

MVA-BN Anthrax-Drug Profile 102

NP-015-Drug Profile 103

obiltoxaximab-Drug Profile 104

oritavancin diphosphate-Drug Profile 106

PBI-220-Drug Profile 109

PreviThrax-Drug Profile 111

Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis-Drug Profile 113

Px-563L-Drug Profile 114

RiVax + VeloThrax-Drug Profile 115

Second Generation Px-563L-Drug Profile 116

SGX-204-Drug Profile 117

Slit2N-Drug Profile 118

Small Molecule to Inhibit Anthrax Toxin for Anthrax-Drug Profile 120

Small Molecules for Bacterial Infections-Drug Profile 121

Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax-Drug Profile 122

Small Molecules to Inhibit Lethal Factor for Anthrax-Drug Profile 123

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis-Drug Profile 125

Small Molecules to Inhibit MMP-Drug Profile 126

SMT-15000-Drug Profile 127

TP-271-Drug Profile 128

Anthrax-Recent Pipeline Updates 130

Anthrax-Dormant Projects 143

Anthrax-Discontinued Products 146

Anthrax-Product Development Milestones 147

Featured News & Press Releases 147

Appendix 157

Methodology 157

Coverage 157

Secondary Research 157

Primary Research 157

Expert Panel Validation 157

Contact Us 157

Disclaimer 158

List of Tables

Number of Products under Development for Anthrax, H1 2015 13

Number of Products under Development for Anthrax-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Anthrax-Pipeline by Aduro BioTech, Inc., H1 2015 27

Anthrax-Pipeline by Aradigm Corporation, H1 2015 28

Anthrax-Pipeline by Bavarian Nordic A/S, H1 2015 29

Anthrax-Pipeline by Bristol-Myers Squibb Company, H1 2015 30

Anthrax-Pipeline by ContraFect Corporation, H1 2015 31

Anthrax-Pipeline by Dynavax Technologies Corporation, H1 2015 32

Anthrax-Pipeline by Elusys Therapeutics, Inc., H1 2015 33

Anthrax-Pipeline by Emergent BioSolutions Inc., H1 2015 34

Anthrax-Pipeline by Evolva SA, H1 2015 35

Anthrax-Pipeline by Green Cross Corporation, H1 2015 36

Anthrax-Pipeline by Grifols, S.A., H1 2015 37

Anthrax-Pipeline by Hawaii Biotech, Inc., H1 2015 38

Anthrax-Pipeline by iBio, Inc., H1 2015 39

Anthrax-Pipeline by Immunovaccine, Inc., H1 2015 40

Anthrax-Pipeline by Innovative Biologics, Inc., H1 2015 41

Anthrax-Pipeline by Microbiotix, Inc., H1 2015 42

Anthrax-Pipeline by NanoBio Corporation, H1 2015 43

Anthrax-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 44

Anthrax-Pipeline by Oragenics, Inc., H1 2015 45

Anthrax-Pipeline by PaxVax, H1 2015 46

Anthrax-Pipeline by Pfenex Inc., H1 2015 47

Anthrax-Pipeline by Planet Biotechnology Inc., H1 2015 48

Anthrax-Pipeline by Protein Potential, LLC, H1 2015 49

Anthrax-Pipeline by ProThera Biologics, LLC., H1 2015 50

Anthrax-Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 51

Anthrax-Pipeline by Revivicor, Inc., H1 2015 52

Anthrax-Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 53

Anthrax-Pipeline by Soligenix, Inc., H1 2015 54

Anthrax-Pipeline by Summit Corporation plc, H1 2015 55

Anthrax-Pipeline by Syntiron LLC, H1 2015 56

Anthrax-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 57

Anthrax-Pipeline by The Medicines Company, H1 2015 58

Anthrax-Pipeline by Vaxin, Inc., H1 2015 59

Assessment by Monotherapy Products, H1 2015 60

Assessment by Combination Products, H1 2015 61

Number of Products by Stage and Target, H1 2015 63

Number of Products by Stage and Mechanism of Action, H1 2015 65

Number of Products by Stage and Route of Administration, H1 2015 67

Number of Products by Stage and Molecule Type, H1 2015 69

Anthrax Therapeutics-Recent Pipeline Updates, H1 2015 133

Anthrax-Dormant Projects, H1 2015 146

Anthrax-Dormant Projects (Contd..1), H1 2015 147

Anthrax-Dormant Projects (Contd..2), H1 2015 148

Anthrax-Discontinued Products, H1 2015 149

List of Figures

Number of Products under Development for Anthrax, H1 2015 13

Number of Products under Development for Anthrax-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Top 10 Targets, H1 2015 62

Number of Products by Stage and Top 10 Targets, H1 2015 62

Number of Products by Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Top 10 Routes of Administration, H1 2015 66

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67

Number of Products by Top 10 Molecule Types, H1 2015 68

Number of Products by Stage and Top 10 Molecule Types, H1 2015 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Aduro BioTech, Inc.

Aradigm Corporation

Bavarian Nordic A/S

Bristol-Myers Squibb Company

ContraFect Corporation

Dynavax Technologies Corporation

Elusys Therapeutics, Inc.

Emergent BioSolutions Inc.

Evolva SA

Green Cross Corporation

Grifols, S.A.

Hawaii Biotech, Inc.

iBio, Inc.

Immunovaccine, Inc.

Innovative Biologics, Inc.

Microbiotix, Inc.

NanoBio Corporation

Navigen Pharmaceuticals, Inc.

Oragenics, Inc.


Pfenex Inc.

Planet Biotechnology Inc.

Protein Potential, LLC

ProThera Biologics, LLC.

PsiOxus Therapeutics, Ltd.

Revivicor, Inc.

SelectX Pharmaceuticals, Inc.

Soligenix, Inc.

Summit Corporation plc

Syntiron LLC

Tetraphase Pharmaceuticals Inc.

The Medicines Company

Vaxin, Inc.

Anthrax Therapeutic Products under Development, Key Players in Anthrax Therapeutics, Anthrax Pipeline Overview, Anthrax Pipeline, Anthrax Pipeline Assessment

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]